Employees Archives - Page 2 of 6 - Juvena Therapeutics

Bek Madjidov

Bek Madjidov is the Head of Finance and Operations at Juvena Therapeutics, responsible for administrative and operational functions (finance, human resources, information technology, and facilities).

Bek is a transformational leader who brings strong business acumen and over 15 years of finance and operations experience in the biotech and high-tech industries. His areas of expertise are strategic planning, business analysis, management reporting, process improvement, and organizational transformation.

Bek previously served as Finance Director at Genentech (Roche), supporting Product Development and Manufacturing Operations organizations. He provided finance leadership to global product and functional teams and led transformational efforts in business and finance organizations. Prior to Genentech, Bek held a variety of finance and leadership roles at Autodesk and Bio-Rad Laboratories by successfully building and leading teams that built strong, cross-functional business partnerships in complex, matrix organizations.

Bek holds a Bachelor of Science (summa cum laude) in Business Administration from the University at Buffalo, State University of New York (SUNY). Bek is pursuing a Master of Business Administration (MBA) from the Haas School of Business at the University of California, Berkeley.

Learn more about Bek
LinkedIn

Back to Careers

Andrew Campbell

Andrew Campbell has 35 years of multi-disciplinary pharmaceutical Quality Assurance experience in both development and commercial stage companies. He has broad experience with parenteral, tablet, and suspension dosage forms. He has assisted several clinical-stage companies through the development cycle, culminating in successful regulatory filings, regulatory inspections, and marketing authorizations.

He has extensive experience with design, remediation, and implementation of Quality Systems. He is an accomplished trainer, speaking to industry groups on the topics of Supplier Management, Auditing, Investigations, and Change Management.

Andrew obtained his Bachelor’s degree in Chemistry from UC Davis.

Learn more about Andrew
LinkedIn

Back to Careers

Jeff Welch

Jeff Welch has over 30 years of CMC experience in the process development, GMP manufacturing and facilities, and regulatory documentation.

In Jeff’s most recent role as a consultant he has had responsibility for authoring and reviewing regulatory filing sections related to process development and product characterization.

Over the past decade Jeff has focused on his role as a senior director for drug substance (DS) process development and director over process engineering and operations for a specialty pharmaceutical company working in biologics and vaccines and as a CDMO organization.

Jeff has also served as a project manager for large scale manufacturing and technology transfer projects and filled the DS team leader role. After a lead role in engineering and construction, he served as a senior manager over the start up effort for a stainless steel cell culture facility (1600 L scale), where he hired and managed personnel and led a 7-day-a-week cGMP manufacturing operation for the upstream portion.

In his early career he participated in design of a multi-product manufacturing facility and after start-up performed process fit and technology transfer activities for several microbial, yeast and cell culture products.

Learn more about Jeff Welch

Back to Careers

Sharon Louie, PhD

Sharon joined Juvena Therapeutics as a Senior Scientist working on preclinical in vivo disease modeling and drug discovery. She received her B.S. in Molecular Toxicology and Ph.D in Metabolic Biology from UC Berkeley where she used chemoproteomic and metabolomic technologies to uncover metabolic drivers of triple-negative breast cancers. Sharon completed her post-doctoral training at Boston Children’s Hospital/Harvard Medical School where she developed a transplantation assay for lung stem cell-derived organoids to mouse models with lung disorders to assess the potential for future cell therapies. She then spent a few years in the biotech industry leading studies to support preclinical drug development.

Sharon has been awarded multiple fellowships during her time in academia, including the NSF graduate fellowship and the Hope Funds for Cancer fellowship. She is a co-author on 22 publications.

Learn more about Sharon
LinkedIn

Back to Careers

Vengadeshprabhu Karuppa gounder, PhD

Dr. Vengadeshprabhu Karuppa gounder, PhD, joined Juvena Therapeutics as a Scientist II working on preclinical in vivo disease modeling and drug discovery. Dr. Karuppa gounder brings over 10 years of pharmacology & drug development experience in academic research. Dr. Karuppa gounder has strong background in pharmacology, immunology and molecular biology. He has several years of experience developing preclinical animal models in areas of diabetes, NASH, cardiomyopathy, autoimmune diseases, aging, osteoarthritis, IBD, renal and inflammatory diseases.

Dr. Karuppa gounder completed his Undergraduate and Master’s work on Pharmaceutical Sciences at the TamilNadu DR. MGR Medical University, Chennai, India and did his Ph.D. studies at Niigata University of Pharmacy and Applied Life Sciences, Japan, where he studied the role of HMGB1 and GPCR role in diabetes and autoimmune disease models. Then he joined as a postdoctoral researcher at Penn State College of Medicine, PA. During his fellowship, Dr. Karuppa gounder established new methods to study the role of GPCR signaling in synovitis, osteoarthritis and osteoporosis in mouse models and treatment options.

Dr. Karuppa gounder achieved the first author in leading scientific journals, Science Translational Medicine, & Aging Research Reviews and co-author of several research and review articles, and bagged several awards and grants.

Learn more about Vengadeshprabhu

Back to Careers

Tina Duong PT, PHD

Tina Duong is the Director of clinical outcomes research and development at Stanford University Neuromuscular division. Clinically, she is a physical therapist with 20 years of clinical experience in evaluating, treating and validating clinical outcomes for patients with neuromuscular disease.

Her clinical and research interests are in developing, refining and understanding impacts of muscle imbalances and pathology on function and performance. Her work has contributed to improved understanding and characterization of disease phenotypes impacting clinical trial design and care management.

Currently, her research focuses on the effect of exercise and physical activity on human movement and disease physiology. She hopes to integrate technology and digital biomarkers as a complementary tool to performance based measures used in trials, in the clinic and remotely. She enjoys working on collaborative diverse inter-disciplinary teams, mentorship and creating patient focused solutions to improve the quality of life for individuals with neuromuscular disease.

Learn more about Tina

LinkedIn

Back to Careers

John W. Day, MD, PhD

Since 2011 John has been Professor of Neurology, Pediatrics (Genetics) and Pathology at Stanford University, where he is Director of the Division of Neuromuscular Medicine. He received his MD from the University of Minnesota, and PhD in Neuroscience from Albert Einstein College of Medicine, where he studied neuronal electrophysiology, synaptic physiology and plasticity. After completing neurology and neuromuscular training at UCSF, he was Professor of Neurology, Pediatrics and Genetics at the University of Minnesota, where he founded and directed the Paul and Sheila Wellstone Muscular Dystrophy Center.

John has investigated the genetic causes and multisystemic effects of neuromuscular disorders and has more than 35 years of experience designing and directing clinical trials of novel therapeutics. He spearheaded clinical research on spinal muscular atrophy (SMA) at Stanford, which resulted in the approval of antisense and AAV-gene replacement treatments, and led to nationwide newborn screening for SMA and institution of neonatal genetic treatment.

Learn more about John

LinkedIn

Back to Careers

Shari-Anne Burgess, RN

Shari Burgess brings over 25 years of clinical experience to the life science and healthcare industry working in a variety of indications such as but not limited to oncology, neuromuscular disorders, rare disease, regenerative medicine, burn and wound care and orthopedics. She is the Chief Clinical Operations Lead in her clinical consulting company, Clinsytes Inc., a niche clinical consulting company that provides global clinical operation insights and solutions for small to midsize life science companies for the improvement of clinical operational performance and delivery of measurables in drug/device development, trial management and business development strategies. Previous to Clinsytes, Shari held senior management roles at CROs and medical/biotech companies.

Learn more about Shari-Anne

LinkedIn

Back to Careers

Ritwik Datta, PHD

Ritwik Datta joined Juvena Therapeutics as a Scientist on the Pharmacology team. Ritwik is a physiologist with over ten years of experience. His expertise lies in comprehending the molecular basis of cardiometabolic diseases. Ritwik’s approach to investigating complex biological questions involves utilizing both mouse models and cell-based methods to develop innovative therapies for cardiometabolic and pulmonary diseases.

Ritwik received his Ph.D. from the University of Calcutta under the guidance of Sagartirtha Sarkar, Ph.D. Ritwik focused on studying how two major cell types in the heart – cardiac myocytes and fibroblasts – communicated with each other through secreted molecules and how these signaling pathways impacted cardiac fibrosis.

Ritwik completed his extensive postdoctoral training at the University of California, San Francisco (UCSF) in the lab of Kamran Atabai, MD. Ritwik’s research identified a novel integrin-mediated feedback loop of insulin receptor signaling that regulates skeletal muscle insulin sensitivity, laying the foundation for integrin-based therapy to lower daily insulin needs in diabetic patients. In his recent work, Ritwik investigated integrins’ role in regulating dietary fat metabolism in the intestine, providing insights into how intestinal lipid droplet homeostasis affects whole-body lipid metabolism and cardiovascular health.

Throughout his career, Ritwik has garnered recognition and support from prestigious organizations, including postdoctoral fellowships from the Larry L Hillblom Foundation, enabling him to pursue his research endeavors. Ritwik has 6, 1st author publications including in PNAS and Cell reports, and he is a co-author of 10 publications in leading scientific journals.

Besides his passion for science, Ritwik is a travel and photography enthusiast.

Learn more about Ritwik

PubMed Library
LinkedIn

Back to Careers

Mingyu Chung, PhD

Min received his B.S. in Electrical Engineering at the University of Michigan and worked for five years as a product engineer at Samsung Austin Semiconductor. He received his Ph.D. in Chemical and Systems Biology at Stanford University, where he researched growth factor and cell cycle signaling in the laboratory of Tobias Meyer. He completed his postdoctoral training at Stanford University (laboratory of Thomas Rando), where he leveraged single-cell genomics and chemical and genetic screening to investigate the mechanisms of skeletal muscle stem cell fate specification. Min received an NIH F32 postdoctoral fellowship and is a co-author on 17 publications.

Learn more about Min
LinkedIn

Bek Madjidov

Andrew Campbell

Jeff Welch

Sharon Louie, PhD

Vengadeshprabhu Karuppa gounder, PhD

Tina Duong PT, PHD

John W. Day, MD, PhD

Shari-Anne Burgess, RN

Ritwik Datta, PHD

Mingyu Chung, PhD

Navigation

Contact

Stay in touch